The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling

Rationale: Lapatinib (LAP) is a crucial alternative to trastuzumab upon the onset of drug resistance during treatment of metastatic human epidermal growth factor receptor 2-positive breast cancer. Like trastuzumab, LAP is commonly used alongside anthracyclines as a combination therapy, due to enhanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Wan-Tseng, Huang, Ching-Ying, Yen, Christopher Y.T., Cheng, Ann-Lii, Hsieh, Patrick C.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010982/
https://www.ncbi.nlm.nih.gov/pubmed/29930721
http://dx.doi.org/10.7150/thno.23207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010982/
https://www.ncbi.nlm.nih.gov/pubmed/29930721
http://dx.doi.org/10.7150/thno.23207

Ejemplares similares